Acute Coronary Syndromes Flashcards
Causes of Plaque Rupture
Chemical Factors:
T-Lymphocytes – secrete gamma interferon which inhibits collagen synthesis, weakening the cap
Cells within the plaque secrete metalloproteinases which degrade the interstitial matrix
Mechanical Stress:
BP, HR, Contractility – SNS activation
Clinical Symptoms of ACS
Typical Symptoms: Sudden chest pressure Radiation down arm (L > R) Diaphoresis Dyspnea Nausea
Atypical Symptoms: Upset stomach – gas pains Syncope Confusion in the elderly Teeth/Jaw pain Mid-Scapular back pain
Labs, Emergent Care, and H and P of Chest Pain
Pain between nose and naval = ACS needs to be looked into
STEMI needs to be identified within 5-10 minutes
Vessel occlusion with STEMI = open up vessel
Initial Labs: 12 lead EKG, cardiac enzymes, electrolytes, CBC, Lipids, BUN/Cr, glucose, CXR
Emergent Care: IV access, cardiac monitoring, O2, Aspirin, and nitrates
H and P: Dx, EKG, complications, assess for reperfusion
Treatment for ACS
Unstable Angina and NSTEMI: medical therapy and assess risk; if low, stress test or meds only; if high, cath lab
STEMI: medical therapy, urgent lytics or cath lab
Medications for ACS
Thrombolytics, Percutaneous Intervention (PCI) Anti-platelets Thrombin Inhibitors HMG-CoA Reductase Inhibitors (Statins) Beta Blockers ACE Inhibitors Nitrates Morphine- last resort
Pathogenesis of a STEMI
Loss of oxygen supply leads to necrosis of viable myocardial tissue beginning within 15 minutes and occurring mainly during 30-90 minutes after acute coronary occlusion
Cath Lab vs. Thrombolytics:
PCI is preferred therapy if possible
Door to balloon time
Types of Stents
- Balloon angioplasty once placed caused dissection flap then causing a thrombus to form = weeks later a different process occurs and neo-intimal hyperplasia of vessel occurs to narrow vessel thus causing angina = not best result and have to fix again
- Bare metal stent: stainless steel scaffolding over it to reduce elastic recoil that occurred after procedure, but thrombus still formed and have to be on anti-platelet therapy but the problem causes further promotion of the neo-intimal hyperplasia as the other stent
- Drug eluting stents: covered with chemical + stainless steel coating to decrease growth (anti-mitotic); higher rates of patency and much more success; standard currently because vessels stay open longer and have less neo-intimal hyperplasia
Fibrinolytics
Thrombolytics are derived from the same substance, t-PA, that is secreted from the endothelium
Activated plasminogen to plasmin to break down fibrin = breaks down clots
Alteplase
Retevase
Tenecteplase
Antiplatelets
Aspirin (ASA); COX inhibitor
Thienopyridines: Ticlodipine, Clopidogrel (Plavix), and Prasugrel (Effient); work at ADP receptors
Direct P2Y12 Inhibitors: Ticangelor (Brilinta); work at ADP receptors
Glycoprotein 2b/3a Inhibitors: (links platelets together) this is the final pathway for inhibition of clot formation
Tirofiban (Aggrastat)
Eptifibatide (Integrelin)
Abciximab (ReoPro)
MACE
New drugs must decrease MACE in order to be approved
Major Adverse Cardiovascular Events Includes: Cardiovascular death Non-fatal myocardial infarction CABG, repeat PCI Stroke
Thienopyridines Mechanism of Action
Thienopyridines: Ticlodipine, Clopidogrel (Plavix), and Prasugrel (Effient); work at ADP receptors
Binds to adenosine diphosphate (ADP) receptor, thus excludes ADP from binding to this platelet receptor
This also inhibits the subsequent ADP mediated activation of the glycoprotein 2b3a complex, which inhibits platelet aggregation.
Approved for UA, NSTEMI, STEMI
Clopidogrel
Platelets are affected for the remainder of their life span.
Upon stopping, it takes approximately 5 days to see an improvement in bleeding times and platelet activation
Must stop 5 days prior to surgery
CURE Trial
CURE: In those with USA/NSTEMI. Significant risk reduction in CV death, MI, CVA at 12 months with ASA + Plavix compared to ASA plus placebo. RRR of 20%, ARR of 2%
Found that patients that received a stent (PCI) had even better risk reduction
Ticlodipine
Not used much anymore due to side effects:
Neutropenia (2%)
TTP (1 in 4000)
Aplastic anemia (1 in 8000)
Prasugrel
Binds irreversibly to the ADP receptor on platelets for their lifespan.
Prasugrel has a greater antiplatelet effect than clopidogrel because it is metabolized more efficiently.
Results in less MACE compared to Plavix
At expense of increased bleeding rates
Also used in conjunction with aspirin
In those undergoing PCI with unstable syndrome only